DOCSLIB.ORG

Manual of Rotavirus Detection and Characterization Methods

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Manual of Rotavirus Detection and Characterization Methods WHO/IVB/08.17 ORIGINAL: ENGLISH Manual of rotavirus detection and characterization methods Immunization, Vaccines and Biologicals WHO/IVB/08.17 ORIGINAL: ENGLISH Manual of rotavirus detection and characterization methods Immunization, Vaccines and Biologicals The Department of Immunization, Vaccines and Biologicals thanks the donors whose unspecified financial support has made the production of this document possible. This document was produced by the Expanded Programme on Immunization of the Department of Immunization, Vaccines and Biologicals Ordering code: WHO/IVB/08.17 Printed: October 2009 This publication is available on the Internet at: www.who.int/vaccines-documents/ Copies of this document as well as additional materials on immunization, vaccines and biologicals may be requested from: World Health Organization Department of Immunization, Vaccines and Biologicals CH-1211 Geneva 27, Switzerland • Fax: + 41 22 791 4227 • Email: [email protected] • © World Health Organization 2009 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 3264; fax: +41 22 791 4857; email: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use. The named authors alone are responsible for the views expressed in this publication. Printed by the WHO Document Production Services, Geneva, Switzerland ii Contents Acknowledgements .............................................................................................................v Using this manual ............................................................................................................ vii 1. Introduction and overview ......................................................................................1 1.1 Background ..........................................................................................................1 1.2 Rotavirus Detection ............................................................................................2 1.3 Rotavirus Characterization .................................................................................4 1.4 Safety precautions .............................................................................................16 1.5 Specimen requirements .....................................................................................17 1.6 Shipping ..............................................................................................................17 2. Laboratory Procedures:Rotavirus Detection .....................................................18 2.1 Virus cultivation .................................................................................................19 2.2 Detection of rotavirus in cell culture by IF .....................................................21 2.3 Electron microscopy (EM) ...............................................................................22 2.4 PAGE and silver staining .................................................................................23 3. Rotavirus characterization: Serological Methods .............................................31 3.1. Serotyping and subgrouping with monoclonal antibodies ............................31 4. Rotavirus characterisation: Molecular methods ................................................47 4.1. Method 1: Manual RNA extraction from stool .............................................47 4.2 Method 2: RNA extraction using hydroxyapatite .........................................49 4.3 Method 3: RNA Extraction Using RNAID ..................................................51 4.4 Method 4: RNA extraction using Trizol ........................................................53 4.5 Method 5: RNA extraction using the CTAB method ...................................54 4.6 Method 6: RNA extraction using the Boom method .....................................55 4.7 Method 7: RNA extraction from cell lysates ..................................................56 4.8 Method 8: G Genotyping ..................................................................................59 4.9 Method 9: P Genotyping .................................................................................63 4.10 Method 10: G Genotyping ................................................................................66 4.11 Method 11: P Genotyping ...............................................................................70 4.12 Method 12: G Genotying .................................................................................73 4.13 Method 13: P Genotyping ...............................................................................77 4.14 Method 14: G genotyping ................................................................................80 4.15 Method 15: P Genotyping ...............................................................................85 4.16 Method 16: G and P genotyping ......................................................................91 4.17 Trouble shooting ...............................................................................................99 5. References ...............................................................................................................100 iii Appendix 1: Oligonucleotide primers ........................................................................104 Appendix 2:Cloning and sequencing methods .........................................................108 Appendix 3: Preparation of reagents .........................................................................132 Appendix 4:Suppliers ....................................................................................................138 Appendix 5:Worksheets ................................................................................................143 iv Acknowledgements This document was produced for the Expanded Programme on Immunization of the Department of Immunization, Vaccines and Biologicals, WHO by the Laboratory Directors of the following Regional Rotavirus Laboratories and the WHO Rotavirus Collaborating Centers: Jon Gentsch WHO Collaborating Center (US) Gastroenteritis and Respiratory Viruses Laboratory Branch Division of Viral Diseases National Center for Immunization and Respiratory Diseases Coordinating Center for Infectious Diseases Centers for Disease Control and Prevention Atlanta, Georgia, US Jim Gray and Miren Iturriza-Gómara European Regional Rotavirus Laboratory Enteric Virus Unit Virus Reference Department Centre for Infections Health Protection Agency London, UK John Klena Eastern Mediterranean Regional Rotavirus Laboratory Enteric Diseases Research Program U.S. Naval Medical Research Unit No. 3 Cairo, Egypt Carl Kirkwood WHO Collaborating Center (Australia) Enteric Virus group Murdoch Childrens Research Institute, Royal Children’s Hospital Victoria, Australia George Armah West African Rotavirus Regional Laboratory Department of Electron Microscopy and Histopathology Noguchi Memorial Institute for Medical Research University of Ghana, Legon, Ghana v Nicola A. Page MRC Diarrhoeal Pathogens Research Unit (DPRU) University of Limpopo (Medunsa Campus) PO Box 173, Medunsa 0204, South Africa The following members of the “Rotavirus Experts External Advisory Group” kindly reviewed and provided helpful comments on the document: Kari Johansen - European Centre for Disease Prevention and Control, Ana Maria Bispo - PAHO, Duncan Steele - PATH and Timo Vesikari - University of Tampere Medical School. vi Using this manual This manual has been prepared by staff of the WHO Rotavirus Collaborating Centers and Regional Laboratories throughout the world and is a comprehensive collection of methods for the detection and characterisation of rotaviruses. The manual should be used in conjunction with the training provided in a Collaborating Centre or Regional Laboratory and contact with that centre should be maintained in order to provide quality assurance and frequent updates of methods. For some of the techniques described, a single method is provided, indicating general consensus among the network of rotavirus laboratories. Where multiple methods
Load more

Recommended publications
  • Evaluation of Six Methods for Extraction and Purification of Viral DNA from Urine and Serum Samples
    NEW MICROBIOLOGICA, 29, 111-119, 2006 Evaluation of six methods for extraction and purification of viral DNA from urine and serum samples Massimiliano Bergallo, Cristina Costa, Giorgio Gribaudo, Sonia Tarallo, Sara Baro, Alessandro Negro Ponzi, Rossana Cavallo Department of Public Health and Microbiology, Virology Unit, University of Turin, Italy SUMMARY The sensitivity and reliability of PCR for diagnostic and research purposes require efficient unbiased procedures of extraction and purification of nucleic acids. One of the major limitations of PCR-based tests is the inhibition of the amplification process by substances present in clinical samples. This study used specimens spiked with a known amount of plasmid pBKV (ATCC 33-1) to compare six methods for extraction and purification of viral DNA from urine and serum samples based on recovery efficiency in terms of yield of DNA and percentage of plasmid pBKV recovered, purity of extracted DNA, and percentage of inhibition. The most effective extraction methods were the phenol/chloroform technique and the silica gel extraction procedure for urine and serum samples, respectively. Considering DNA purity, the silica gel extraction procedure and the phenol/chloroform method produced the most satisfactory results in urine and serum samples, respectively. The presence of inhibitors was overcome by all DNA extraction techniques in urine samples, as evidenced by semiquantitative PCR amplification. In serum samples, the lysis method and the proteinase K procedure did not completely overcome the presence of inhibitors. KEY WORDS: PCR, DNA extraction, BKV, PCR inhibitors Received February 8, 2006 Accepted March 14, 2006 INTRODUCTION sequences has allowed the determination of pres- ence and quantification of specific viral genes and Molecular biology techniques represent a pow- sequences in biological matrices.
    [Show full text]
  • Introduction of Human Telomerase Reverse Transcriptase to Normal Human Fibroblasts Enhances DNA Repair Capacity
    Vol. 10, 2551–2560, April 1, 2004 Clinical Cancer Research 2551 Introduction of Human Telomerase Reverse Transcriptase to Normal Human Fibroblasts Enhances DNA Repair Capacity Ki-Hyuk Shin,1 Mo K. Kang,1 Erica Dicterow,1 INTRODUCTION Ayako Kameta,1 Marcel A. Baluda,1 and Telomerase, which consists of the catalytic protein subunit, No-Hee Park1,2 human telomerase reverse transcriptase (hTERT), the RNA component of telomerase (hTR), and several associated pro- 1School of Dentistry and 2Jonsson Comprehensive Cancer Center, University of California, Los Angeles, California teins, has been primarily associated with maintaining the integ- rity of cellular DNA telomeres in normal cells (1, 2). Telomer- ase activity is correlated with the expression of hTERT, but not ABSTRACT with that of hTR (3, 4). Purpose: From numerous reports on proteins involved The involvement of DNA repair proteins in telomere main- in DNA repair and telomere maintenance that physically tenance has been well documented (5–8). In eukaryotic cells, associate with human telomerase reverse transcriptase nonhomologous end-joining requires a DNA ligase and the (hTERT), we inferred that hTERT/telomerase might play a DNA-activated protein kinase, which is recruited to the DNA role in DNA repair. We investigated this possibility in nor- ends by the DNA-binding protein Ku. Ku binds to hTERT mal human oral fibroblasts (NHOF) with and without ec- without the need for telomeric DNA or hTR (9), binds the topic expression of hTERT/telomerase. telomere repeat-binding proteins TRF1 (10) and TRF2 (11), and Experimental Design: To study the effect of hTERT/ is thought to regulate the access of telomerase to telomere DNA telomerase on DNA repair, we examined the mutation fre- ends (12, 13).
    [Show full text]
  • Advancing Gene Fusion Detection Towards Personalized Cancer Nanodiagnostics Kevin Maisheng Koo Bachelor of Science (Hons I)
    Advancing Gene Fusion Detection towards Personalized Cancer Nanodiagnostics Kevin Maisheng Koo Bachelor of Science (Hons I) A thesis submitted for the degree of Doctor of Philosophy at The University of Queensland in 2017 Australian Institute for Bioengineering and Nanotechnology Abstract Prostate cancer (PCa) is one of the most prevalent non-cutaneous cancers in men, and is also one of the most lethal oncogenic diseases that accounts for a vast majority of male cancer-related deaths. Currently, widespread PCa screening is reliant on the prevailing usage of the FDA-approved blood- based prostate specific antigen (PSA) biomarker. Yet, landmark clinical trials in recent years have indicated that serum PSA screening holds a substantial risk of over-diagnosing low grade indolent PCa which are unlikely to result in mortality. Consequently, this paucity of accurate disease risk stratification during PCa screening has led to a variety of health burden associated with unnecessary biopsies, and over-treatment in a considerable fraction of patient population. Given that the screening shortcoming of the PSA test is outweighing its benefit, there is a clear need for better strategies to improve PCa risk stratification and accurately detect high-grade aggressive PCa molecular subtypes at an early stage for timely personalized treatment. To address this PCa screening conundrum, the research work described in this thesis primarily embodies a bipartite strategy which pairs together the use of next-generation PCa-specific molecular biomarkers, and the development of innovative nanodiagnostic technologies to target these superior biomarkers. In recent years, massive advances in next-generation sequencing techniques have led to the discoveries of novel PCa molecular targets which possess excellent PCa- specificity (i.e.
    [Show full text]
  • Purification and Characterization of the Reverse Transcriptase Expressed In
    Volume 270, number 1,2, 76-80 FEBS 08845 September 1990 Purification and characterization of the RNase H domain of HIV-l reverse transcriptase expressed in recombinant Escherichia coli S. Patricia Becerra’, G. Marius Clore2, Angela M. Gronenbornz, Anders R. Karlstr6m3, Stephen J. Stahl‘+, Samuel H. Wilson’ and Paul T. Wingfield 1Laboratory of Biochemistry, NCI, ZLaboratory of Chemical Physics, NIDDK, 3Laboratory of Biochemistry, NHLB and 4Protein Expression Laboratory, National Institutes of Health, Bethesda, MD 20892, USA Received 2 July 1990 The ribonuclease H (RNase H) domain of human immuno-deficiency virus (HIV-l) reverse transcriptase has been produced with the aim of provid- ing sufficient amounts of protein for biophysical studies. A plasmid vector is described which directs high level expression of the RNase H domain under the control of the I PL promoter. The domain corresponds to residues 427-560 of the 66 kDa reverse transcriptase. The protein was expressed in Escherichia cob’ and was purified using ion-exchange and size exclusion chromatography. The purified protein appears to be in a native-like homogeneous conformational state as determined by iH-NMR spectroscopy and circular dichroism measurements. HIV-protease treatment of the RNase H domain resulted in cleavage between Phe-440 and Tyr-441. HIV-l reverse transcriptase; HIV-l RNase H; HIV protease; Protein expression; Protein purification; Protein conformation 1. INTRODUCTION as a separate 15 kDa protein. The purified protein ap- pears suitable for structural studies by both NMR spec- Ribonuclease H (RNase H) activity resides in the C- troscopy and X-ray analysis, thereby providing an addi- terminal region of retroviral polymerases as shown by tional target in the search for therapeutic agents against deletion experiments [ 11, linker insertion [2] and point the spread of HIV infection.
    [Show full text]
  • Rapidxfire Thermostable Reverse Transcriptase Application Note
    Application note RapiDxFire Thermostable Reverse Transcriptase Introduction RNA target, which improves cDNA yield and A reverse transcriptase (RT) is a DNA subsequent detection sensitivity from difficult polymerase enzyme that synthesises cDNA RNA targets. Thermostability also is an from an RNA template. RTs are widely indicator of general enzyme stability for storage, used to study gene expression in cells or automation applications, and lyophilisation. tissues, in next-generation sequencing Processivity, which refers to the number of (NGS) applications, and in conjunction with nucleotides incorporated into cDNA during quantitative PCR (qPCR) or isothermal a single enzyme binding event, can affect amplification methods to detect and identify cDNA length, RT efficiency, and RT reaction RNAs that are of clinical or functional time. Native RT enzymes also have RNase H significance. endonuclease activity that will cleave the RNA from a DNA-RNA duplex and limit cDNA length. RT enzymes may differ in key characteristics Some RT variants also have been engineered that affect their performance in different to reduce RNase H activity to allow longer applications. Their thermostability allows cDNA products. cDNA synthesis to be performed at higher temperatures (above 50 °C), enabling them Commercially available RTs used in molecular to melt areas of secondary structure in the biology are generally derived from Moloney Application note RapiDxFire Thermostable Reverse Transcriptase murine leukaemia virus (MMLV) or avian Skeletal Muscle Total RNA (Thermo Fisher myeloblastosis virus (AMV), which have optimal Scientific Cat No. AM7982), RNA, MS2 (Roche activity at 37-42 °C. Cloned AMV RT and Cat No. 10165948001), Zika virus ATCC® engineered variants of AMV RT and MMLV VR-1843™ (ATCC Cat No.
    [Show full text]
  • Herpes Simplex Virus Type 1 Oril Is Not Required for Virus Infection In
    JOURNAL OF VIROLOGY, Nov. 1987, p. 3528-3535 Vol. 61, No. 11 0022-538X/87/113528-08$02.00/0 Copyright C 1987, American Society for Microbiology Herpes Simplex Virus Type 1 oriL Is Not Required for Virus Replication or for the Establishment and Reactivation of Latent Infection in Mice MARYELLEN POLVINO-BODNAR, PAULO K. ORBERG, AND PRISCILLA A. SCHAFFER* Laboratory of Tumor Virus Genetics, Dana-Farber Cancer Institute, and Department of Microbiology and Molecular Genetics, Harvard Medical School, Boston, Massachusetts 02115 Received 11 May 1987/Accepted 31 July 1987 During the course of experiments designed to isolate deletion mutants of herpes simplex virus type 1 in the gene encoding the major DNA-binding protein, ICP8, a mutant, d61, that grew efficiently in ICP8-expressing Vero cells but not in normal Vero cells was isolated (P. K. Orberg and P. A. Schaffer, J. Virol. 61:1136-1146, 1987). d61 was derived by cotransfection of ICP8-expressing Vero cells with infectious wild-type viral DNA and a plasmid, pDX, that contains an engineered 780-base-pair (bp) deletion in the ICP8 gene, as well as a spontaneous -55-bp deletion in OriL. Gel electrophoresis and Southern blot analysis indicated that d61 DNA carried both deletions present in pDX. The ability of d61 to replicate despite the deletion in OriL suggested that a functional OriL is not essential for virus replication in vitro. Because d61 harbored two mutations, a second mutant, ts+7, with a deletion in oriL-associated sequences and an intact ICP8 gene was constructed. Both d61 and ts+7 replicated efficiently in their respective permissive host cells, although their yields were slightly lower than those of control viruses with intact oriL sequences.
    [Show full text]
  • Virus Purification, Rna Extraction, and Targeted
    VIRUS PURIFICATION, RNA EXTRACTION, AND TARGETED GENOME CAPTURE IN ONE CHIP Miyako Niimi1*, Taisuke Masuda1, Kunihiro Kaihatsu2, Nobuo Kato2, and Fumihito Arai1 1Nagoya University, JAPAN and 2Osaka University, JAPAN ABSTRACT In this research, we demonstrated a microfluidic chip to pretreat the samples for viral genome assay. The microfluidic chip has the following three functions; (1) Virus purification and enrichment, (2) Viral RNA extraction, and (3) Capture of the targeted virus genome. (1) Hydroxyapatite chromatography, Boom method, and PNA (2) (Peptide Nucleic Acid) were used for the above three (3) functions, respectively. These three functions were integrated in one chip. Furthermore PNA immobilized on the glass can detect the targeted virus genome so that in situ virus detection would be possible by anybody, anywhere, anytime. KEYWORDS: Virus purification, RNA extraction and detection, Infectious disease diagnosis INTRODUCTION For the purpose of diagnosing the infectious diseases Figure 1. Concept of the microfluidic chip. The microflu- quickly and accurately, DNA sequencers for gene analysis idic chip consists of the three parts: (1) hydroxyapatite- of infectious viruses have been developed rapidly. The packed microcolumn for virus purification, (2) silica- latest DNA sequencers can treat the massive numbers of packed microcolumn for viral RNA extraction, and (3) samples such as saliva and nasal at one time. However, it PNA immobilized glass for capture of the targeted virus is necessary to purify and enrich the virus and extract the genome. viral RNA in the sample as the pretreatments before gene (1) (2) analysis. Hydroxyapatite chromatography[1] have been Sample Elution Buffer used extensively for purification and fractionation of Hydroxy- various biochemical substances such as protein and virus.
    [Show full text]
  • Foamy Virus Assembly with Emphasis on Pol Encapsidation
    Viruses 2013, 5, 886-900; doi:10.3390/v5030886 OPEN ACCESS viruses ISSN 1999-4915 www.mdpi.com/journal/viruses Review Foamy Virus Assembly with Emphasis on Pol Encapsidation Eun-Gyung Lee 1, Carolyn R. Stenbak 2 and Maxine L. Linial 1,* 1 Fred Hutchinson Cancer Research Center, Basic Sciences Division; 1100 Fairview Avenue North, Seattle, WA 98109, USA; E-Mails: [email protected] (EGL); [email protected] (MLL) 2 Seattle University, Biology Department; 901 12th Avenue, Seattle, WA 98122, USA; E-Mail: [email protected] * Authors to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +1-206- 667-4442; Fax: +1-206-667-5939 Received: 31 January 2013; in revised form: 11 March 2013 / Accepted: 14 March 2013 / Published: 20 March 2013 Abstract: Foamy viruses (FVs) differ from all other genera of retroviruses (orthoretroviruses) in many aspects of viral replication. In this review, we discuss FV assembly, with special emphasis on Pol incorporation. FV assembly takes place intracellularly, near the pericentriolar region, at a site similar to that used by betaretroviruses. The regions of Gag, Pol and genomic RNA required for viral assembly are described. In contrast to orthoretroviral Pol, which is synthesized as a Gag-Pol fusion protein and packaged through Gag-Gag interactions, FV Pol is synthesized from a spliced mRNA lacking all Gag sequences. Thus, encapsidation of FV Pol requires a different mechanism. We detail how WT Pol lacking Gag sequences is incorporated into virus particles. In addition, a mutant in which Pol is expressed as an orthoretroviral-like Gag-Pol fusion protein is discussed.
    [Show full text]
  • Topological Analysis of the Gp41 MPER on Lipid Bilayers Relevant to the Metastable HIV-1 Envelope Prefusion State
    Topological analysis of the gp41 MPER on lipid bilayers relevant to the metastable HIV-1 envelope prefusion state Yi Wanga,b, Pavanjeet Kaurc,d, Zhen-Yu J. Sune,1, Mostafa A. Elbahnasawya,b,2, Zahra Hayatic,d, Zhi-Song Qiaoa,b,3, Nhat N. Buic, Camila Chilea,b,4, Mahmoud L. Nasre,5, Gerhard Wagnere, Jia-Huai Wanga,f, Likai Songc, Ellis L. Reinherza,b,6, and Mikyung Kima,g,6 aLaboratory of Immunobiology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115; bDepartment of Medicine, Harvard Medical School, Boston, MA 02115; cNational High Magnetic Field Laboratory, Florida State University, Tallahassee, FL 32306; dDepartment of Physics, Florida State University, Tallahassee, FL 32306; eDepartment of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115; fDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215; and gDepartment of Dermatology, Harvard Medical School, Boston, MA 02215 Edited by Peter Palese, Icahn School of Medicine at Mount Sinai, New York, NY, and approved September 23, 2019 (received for review July 18, 2019) The membrane proximal external region (MPER) of HIV-1 envelope immunologically vulnerable epitopes targeted by several of the most glycoprotein (gp) 41 is an attractive vaccine target for elicitation of broadly neutralizing antibodies (bNAbs) developed during the broadly neutralizing antibodies (bNAbs) by vaccination. However, course of natural HIV-1 infection (10–13). Insertion, deletion, current details regarding the quaternary structural organization of and mutations of residues in the MPER defined the functional the MPER within the native prefusion trimer [(gp120/41)3] are elu- importance of the MPER in Env incorporation, viral fusion, and sive and even contradictory, hindering rational MPER immunogen infectivity (14–16).
    [Show full text]
  • HIV-1 Rev Downregulates Tat Expression and Viral Replication Via Modulation of NAD(P)H:Quinine Oxidoreductase 1 (NQO1)
    ARTICLE Received 25 Jul 2014 | Accepted 22 Apr 2015 | Published 10 Jun 2015 DOI: 10.1038/ncomms8244 HIV-1 Rev downregulates Tat expression and viral replication via modulation of NAD(P)H:quinine oxidoreductase 1 (NQO1) Sneh Lata1,*, Amjad Ali2,*, Vikas Sood1,2,w, Rameez Raja2 & Akhil C. Banerjea2 HIV-1 gene expression and replication largely depend on the regulatory proteins Tat and Rev, but it is unclear how the intracellular levels of these viral proteins are regulated after infection. Here we report that HIV-1 Rev causes specific degradation of cytoplasmic Tat, which results in inhibition of HIV-1 replication. The nuclear export signal (NES) region of Rev is crucial for this activity but is not involved in direct interactions with Tat. Rev reduces the levels of ubiquitinated forms of Tat, which have previously been reported to be important for its transcriptional properties. Tat is stabilized in the presence of NAD(P)H:quinine oxidoreductase 1 (NQO1), and potent degradation of Tat is induced by dicoumarol, an NQO1 inhibitor. Furthermore, Rev causes specific reduction in the levels of endogenous NQO1. Thus, we propose that Rev is able to induce degradation of Tat indirectly by downregulating NQO1 levels. Our findings have implications in HIV-1 gene expression and latency. 1 Department of Microbiology, University College of Medical Sciences and Guru Teg Bahadur Hospital, Delhi 110095, India. 2 Laboratory of Virology, National Institute of Immunology, New Delhi 110067, India. * These authors contributed equally to this work. w Present address: Translational Health Science and Technology Institute, Faridabad, Haryana 121004, India. Correspondence and requests for materials should be addressed to A.C.B.
    [Show full text]
  • Opportunistic Intruders: How Viruses Orchestrate ER Functions to Infect Cells
    REVIEWS Opportunistic intruders: how viruses orchestrate ER functions to infect cells Madhu Sudhan Ravindran*, Parikshit Bagchi*, Corey Nathaniel Cunningham and Billy Tsai Abstract | Viruses subvert the functions of their host cells to replicate and form new viral progeny. The endoplasmic reticulum (ER) has been identified as a central organelle that governs the intracellular interplay between viruses and hosts. In this Review, we analyse how viruses from vastly different families converge on this unique intracellular organelle during infection, co‑opting some of the endogenous functions of the ER to promote distinct steps of the viral life cycle from entry and replication to assembly and egress. The ER can act as the common denominator during infection for diverse virus families, thereby providing a shared principle that underlies the apparent complexity of relationships between viruses and host cells. As a plethora of information illuminating the molecular and cellular basis of virus–ER interactions has become available, these insights may lead to the development of crucial therapeutic agents. Morphogenesis Viruses have evolved sophisticated strategies to establish The ER is a membranous system consisting of the The process by which a virus infection. Some viruses bind to cellular receptors and outer nuclear envelope that is contiguous with an intri‑ particle changes its shape and initiate entry, whereas others hijack cellular factors that cate network of tubules and sheets1, which are shaped by structure. disassemble the virus particle to facilitate entry. After resident factors in the ER2–4. The morphology of the ER SEC61 translocation delivering the viral genetic material into the host cell and is highly dynamic and experiences constant structural channel the translation of the viral genes, the resulting proteins rearrangements, enabling the ER to carry out a myriad An endoplasmic reticulum either become part of a new virus particle (or particles) of functions5.
    [Show full text]
  • Amplication of 0.7Kb Fragment Katg Gene from Clinical Multi Drug Resistant Tuberculosis Isolate in Bali
    Indonesian Journal of Biomedical Sciences Volume 7, Number 2, July-December 2013: 69-72 Print-ISSN: 2085-4773, E-ISSN: 2302-2906. AMPLICATION OF 0.7KB FRAGMENT KATG GENE FROM CLINICAL MULTI DRUG RESISTANT TUBERCULOSIS ISOLATE IN BALI 1Dwiputri, A. W., 2Ratnayani, K., 1Yowani, S. C. 1Department of Pharmacy, Faculty of Mathematics and Natural Sciences, Udayana University, Bali-Indonesia 2Department of Chemistry, Faculty of Mathematics and Natural Sciences, Udayana University, Bali-Indonesia ABSTRACT During last decade has seen a particular increase in the occurrence of drug-resistant of tuberculosis (DR-TB) and multi-DR strains, such as Isoniazid (INH) resistant strains of M. tuberculosis. INH resistance is more frequently associated with mutations in the katG gene. Detection of katG gene mutations can be performed by PCR technique, followed by sequences. The aim of this study is to amplify katG gene region (0,7 Kb) from clinical isolate of MDR-TB in Bali. DNA isolation for PCR was done by Boom method and katG gene amplification was performed under the following conditions: predenaturation at 950C for 15 min; fourty cycles of denaturation at 940C for 1 min, annealing at 560C for 1 min, extension at 720C for 2 min; final extension at 720C for 10 min. The amplicons were detected by 1.5% agarose gel electrophoresis and showed a specific band size at 0.7 kb. This suggests that the fragment of katG gene has been successfully amplified in these areas. Keywords: amplification, katG gene, MDR-TB, 0.7 Kb INTRODUCTION we designed new primers with a longer area of Tuberculosis, caused by M.
    [Show full text]